(VIANEWS) – Shares of Exact Sciences (NASDAQ: EXAS) rose by a staggering 29.69% in 21 sessions from $63.55 at 2023-04-25, to $82.42 at 15:08 EST on Wednesday, following the last session’s downward trend. NASDAQ is dropping 0.75% to $12,466.27, following the last session’s downward trend.
Exact Sciences’s last close was $82.00, 2.07% under its 52-week high of $83.73.
About Exact Sciences
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Earnings Per Share
As for profitability, Exact Sciences has a trailing twelve months EPS of $-2.86.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -16.36%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 23.8%, now sitting on 2.2B for the twelve trailing months.
Yearly Top and Bottom Value
Exact Sciences’s stock is valued at $82.42 at 15:08 EST, below its 52-week high of $83.73 and way above its 52-week low of $29.27.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Exact Sciences’s EBITDA is 7.34.
More news about Exact Sciences (EXAS).
